-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 2, YZJ-1139, a class 1 new drug of Yangtze River Pharmaceutical, launched a large-scale Phase 3 clinical trial to treat insomnia
.
From Insight database (http://db.
dxy.
cn/v5/home/)
Orexin is a neuropeptide that is naturally produced by the hypothalamus and mainly acts on the central nervous system
.
It has a wide range of effects in regulating food intake, energy metabolism balance, wake-up cycle, blood pressure and so on .
YZJ-1139 is a highly effective antagonist of orexin type 1 and type 2 dual receptors (OX1R and OX2R), which can improve sleep by inhibiting orexin receptors, including speeding up sleep and prolonging sleep time
.
At the same time, YZJ-1139 has the advantages of fast absorption and moderate half-life, which can achieve rapid onset and low residual effect the next day
On May 16, 2021, at the Third Sleep Conference of the Asian Society of Sleep Medicine (ASSM 2021), Yang Zijiang announced the Phase 2 clinical data of YZJ-1139.
The trial data showed that YZJ-1139 can improve sleep by inhibiting orexin receptors.
, Can safely and effectively improve the sleep efficiency of patients with insomnia, and has a dose-effect relationship
.
This is the first orexin receptor antagonist that has completed Phase 2 clinical trials in China
YZJ-1139 first submitted its clinical application in May 2016, and started clinical trials for the first time in August 2017.
Note: The original text has been deleted
